Ann: Bod expands medicinal cannabis product suite, page-4

ASX rules legsilate "continuous disclosure" so events must be disclosed when they are confirmed 

Domestic markets remain important but the only reason to own BOD is UK and European opportunity with CBD and China (with help from new Blackmores staff) with neutraceuticals

Any announcment on these would be a significant catalyst on market cap IMO - we have seen it with EXL and once they go you dont get another chance (from what I have seen)

The new Lambert IPO and EXL have marekt caps over 300 Mill and revenues over 10 Mill annually - even if BOD only makes 3 Mill revenues in next 12 months it would suggest major market cap potntial from current levels on relative value basis ?? My OPIONION only is right mrket cap should be circa 70-80 Mill based on risk weighted outcomes on revenue growth so a share price 70-80 cents ish ....

If they do deliver 3-5 Mill in revenues over next 12 month a target price of $1 - $1.5o is where I see stock. 

I used same analysis on EXL (check my posts from last year) and said I thought $3.00 for them .....